how to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?

Authors

babak fallahi

research center for nuclear medicine, shariati hospital, tehran university of medical sciences, tehran, iran armaghan fard-esfahani

research center for nuclear medicine, shariati hospital, tehran university of medical sciences, tehran, iran alireza emami-ardekani

research center for nuclear medicine, shariati hospital, tehran university of medical sciences, tehran, iran somayeh sahari

research center for nuclear medicine, shariati hospital, tehran university of medical sciences, tehran, iran davood beiki

abstract

introduction:differentiated thyroid carcinoma (dtc) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (tg), diagnostic iodine-131 whole body scan (dxwbs) and sonography. some patients with undetectable tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. methods: in this study, we enrolled dtc patients with undetectable tg but small thyroid residue in six-month-dxwbs following first radioiodine-ablation. patients with detectable tg, high tgab, suspicious neck lymphadenopathy in sonography and metastasis were excluded. ninety four patients were placed in two groups of cohort, i.e., radioiodine-retreatment group (n=36) versus observation (untreated) group (n=58). after six months, the clinical outcome was compared by evaluating dxwbs, tg, tgab and sonography. results: dxwbs showed sustained thyroid remnant in 47.2% of retreated patients while 34.5% of untreated group revealed negative dxwbs over the next period of follow-up. also, only 6 cases (16.7%) in retreatment group and 12 cases (20.7%) in observation group revealed an additional finding other than local faint rai uptake, including detectable serum tg, rising tgab or suspicious ultrasound finding, favoring no significant difference of the outcome as well as relative risk of new finding incidence between treated and untreated patients (ci 95% for relative risk: 0.58-2.41; p=0.630). conclusion: regarding sonologic and laboratory follow-up evidences, rai-retreatment shows no significant advantage over observation in dtc patients with tg negative, remnant positive dxwbs. in addition, residual thyroid tissue was completely disappeared in about one third of patients without retreatment.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?

Introduction:Differentiated thyroid carcinoma (DTC) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (Tg), diagnostic iodine-131 whole body scan (DxWBS) and sonography. Some patients with undetectable Tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. Me...

full text

How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?

Introduction: Differentiated thyroid carcinoma (DTC) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (Tg), diagnostic iodine-131 whole body scan (DxWBS) and sonography. Some patients with undetectable Tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. Methods: In this study, we ...

full text

Evaluation of response to I-131 ablative therapy in patients with differentiated thyroid carcinoma: A five year retrospective study [Persian]

Differentiated thyroid carcinomas usually show good uptake and response to I-131 ablative treatment. In this study, 90 patients following near total thyroidectomy who were referred to our institute for I-131 therapy are retrospectively studied. The patients are divided in two groups. Group 1 revealed complete ablation after one dose of I-131. Group 2 needed more than one dose of I-131 for...

full text

Differentiated thyroid carcinoma referred for radioiodine therapy.

OBJECTIVE The current work was conducted to study the disease status and treatment results of patients with differentiated thyroid carcinoma referred for radioactive iodine therapy. METHODS Retrospective review of 78 patients with differentiated thyroid carcinoma referred for radioiodine therapy in the Nuclear Medicine Unit, King Abdulaziz Hospital and Oncology Center, Jeddah, Kingdom of Saud...

full text

Radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [Persian]

Salivary gland involvement is one of the radioiodine therapy complications. Salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. Methods: Salivary gland scintigraphy was performed with Tc-99m Pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. Ejection Fraction (EF) of parotid and submandibula...

full text

Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma.

The aim of the study was to investigate the influence of radioiodine (RAI) therapy on pregnancies and the health status of children born to mothers who had received therapeutic doses of I-131 for differentiated thyroid carcinoma (DTC). Gestational histories of 76 women treated for DTC from 1971-2005 were retrospectively analyzed. The outcome of 49 pregnancies after RAI was: 35 children (72%), 5...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of nuclear medicine

جلد ۲۵، شماره ۱، صفحات ۵۱-۵۹

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023